Prof Liang Wang speak to ecancer about results from a prospective phase 2 trial evaluating CD19 CD22 bispecific CAR T cell therapy in patients with relapsed or refractory large B cell lymphoma. The study also explores mechanistic insights into treatment response using single cell sequencing and laboratory analyses.

Prof Wang says that among 73 heavily pretreated patients, the therapy demonstrated strong efficacy, with an overall response rate of 95.9 percent and complete responses in over half of patients.

Survival outcomes were encouraging, with durable responses and high estimated progression free and overall survival rates at two years.

The safety profile was manageable, with expected haematologic toxicities and mostly low grade cytokine release syndrome. Neurotoxicity was infrequent, and no treatment related deaths were observed.

Mechanistic analyses revealed that enrichment of specific CD4 positive T cell subsets, along with activation of interferon signaling and viral mimicry pathways, were associated with improved outcomes.

These findings support CD19 CD22 bispecific CAR T therapy as a promising strategy to overcome resistance and improve durability of response in relapsed or refractory large B cell lymphoma.